Related Experiment Video

Updated: May 23, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Lapatinib for advanced or metastatic breast cancer

Frans L Opdam1, Henk-Jan Guchelaar, Jos H Beijnen

  • 1The Netherlands Cancer Institute, Department of Clinical Pharmacology, Postbus 90203, 1006 BE Amsterdam, The Netherlands.

The Oncologist
|April 6, 2012
PubMed

Insights

Lapatinib is an effective targeted therapy for HER2-positive breast cancer, offering a new treatment option. Further research is needed to compare its efficacy directly with trastuzumab in various breast cancer settings.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lapatinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).
  • It is approved for advanced or metastatic HER2-positive breast cancer and hormone receptor-positive breast cancer.

Purpose of the Study:

  • To review the role of lapatinib in breast cancer treatment.
  • To highlight the need for comparative studies with trastuzumab.

Main Methods:

  • Review of existing clinical data and studies on lapatinib.
  • Identification of ongoing clinical trials for further evaluation.

Main Results:

  • Lapatinib is generally well-tolerated, with rash and gastrointestinal issues as primary toxicities.
  • Direct comparative efficacy data between lapatinib and trastuzumab are currently limited.

Conclusions:

  • Lapatinib represents a valuable therapeutic option for specific breast cancer subtypes.
  • Results from ongoing Phase III trials will be crucial for establishing its comparative effectiveness against trastuzumab.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...